What Sensorium Therapeutics does

Sensorium Therapeutics is a clinical-stage central nervous system (CNS) biotechnology company developing first-in-class psychoactive medicines derived from natural products and identified through its proprietary SensAI discovery platform. Founded in 2021 by researchers from Harvard Medical School and Massachusetts General Hospital, the company is headquartered in Cambridge, Massachusetts, and operates with 11–50 employees. Its pipeline comprises three programs: SENS-01 (lead clinical asset SNTX-2643, a state-selective serotonin transporter modulator for social anxiety disorder, currently in Phase 1 trials), SENS-03 (preclinical candidate for drug-resistant epilepsy with development candidate nomination expected in 2H 2026), and SENS-08 (NIH-funded discovery program targeting Alzheimer's-related cognitive impairment). Topline Phase 1a results for SNTX-2643 are expected in the second half of 2026.

The company's core technology is the SensAI platform, which integrates expert-curated data spanning more than 700,000 natural products, 100,000+ plants, 250,000+ ethnobotanical references, and 1M+ bioassays into a unified knowledge graph of over 50 million relationships across chemistry, pharmacology, neuroscience, and human therapeutic experience. AI-driven pattern recognition across this graph identifies therapeutic signals that screening-based approaches cannot systematically detect, supporting the company's claim of producing three differentiated programs in under three years. The company has built a robust intellectual property estate extending into the 2040s and has received FDA IND clearance for SNTX-2643.

Sensorium is pre-revenue and intends to commercialize approved products through traditional pharmaceutical distribution channels (specialty pharmacies, wholesale distributors, hospital and health system purchasing). The company has raised approximately $55 million in venture funding across a $30 million Series A (November 2022, led by Route 66 Ventures, Santé Ventures, and The CU Healthcare Innovation Fund) and a $25 million Series A extension (August 2025, with Mission BioCapital, Dolby Family Ventures, Hatteras Ventures, and Mockingbird Capital), supplemented by a $3.5 million NIH award supporting SENS-08. Leadership includes co-founder Jacob Hooker, PhD as CEO, Simba Gill, PhD as Executive Chairman, Cole Brown, M.D. as CMO (appointed May 2026), Evan Gibson as CBO, and Alex Simon as Chief of Staff, with a board including representatives from Santé Ventures, Mission BioCapital, and Route 66 Ventures.

Name

Sensorium Therapeutics

Legal name

Sensorium Therapeutics, Inc.

Website

https://sensorium.bio

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Sensorium Therapeutics is a clinical-stage CNS biotechnology company developing first-in-class psychoactive medicines for anxiety, drug-resistant epilepsy, and Alzheimer's-related cognitive impairment, identified through its proprietary SensAI AI-driven natural product discovery platform.

Ownership category

akta.pro rank

Product category

CNS Therapeutics

NAICS

Other Scientific and Technical Consulting Services (54169), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Nanotechnology (541713)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Neurology/CNS Gene Therapies (HLAAACAH)

Keywords

• CNS therapeutics
• AI drug discovery
• Psychoactive medicines
• Natural product pharmaceuticals
• Clinical-stage biotechnology

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Drug Sales: Pre-revenue clinical stage biotech. Revenue will be generated through commercialization of CNS therapeutics following FDA approval. Lead program SNTX-2643 (SENS-01) in Phase 1 for anxiety disorders. Additional programs in drug-resistant epilepsy (SENS-03) and cognitive enhancement (SENS-08).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Sensorium Therapeutics is a clinical-stage CNS biotechnology company that develops nature-derived, AI-guided psychoactive medicines for anxiety disorders, drug-resistant epilepsy, and neurodegenerative cognitive impairment. The company's core offering centers on its proprietary SensAI discovery platform combined with a pipeline of three differentiated drug programs (SENS-01/SNTX-2643 in Phase 1 for anxiety; SENS-03 preclinical for epilepsy; SENS-08 discovery for cognitive dysfunction), with revenue intended from pharmaceutical sales and licensing upon FDA approval.

Product overview

Sensorium Therapeutics is a clinical-stage biotechnology company developing a unified product portfolio centered on its proprietary SensAI™ AI-powered drug discovery platform, which integrates chemistry, pharmacology, neuroscience, and ethnobotanical data across 50+ million curated relationships. The platform has produced three differentiated CNS drug programs: SENS-01 (lead Phase 1 program for social anxiety disorder featuring investigational therapy SNTX-2643, a first-in-class serotonin transporter modulator), SENS-03 (preclinical lead candidate for drug-resistant epilepsy), and SENS-08 (NIH-funded discovery program for Alzheimer's-related cognitive impairment).

Differentiator

Problem solved

Functional benefit

Brands

• SensAI: Proprietary discovery platform integrating expert-curated natural product data, proprietary AI tools, and chemical analysis that identifies patterns across 50+ million data relationships to guide new drug discovery.

Products and services

• SENS-01 (SNTX-2643) Lead clinical program advancing a novel state-selective serotonin transporter (SERT) modulator (SNTX-2643) for social anxiety disorder (SAD) and generalized anxiety disorder (GAD). Re-engineered from a natural product with a long history of human use, designed for rapid onset of action, reduced off-target side effects, and avoidance of sedation compared to SSRIs and benzodiazepines. Currently in Phase 1 evaluating safety, pharmacokinetics, and target engagement biomarkers.
• SENS-03 Preclinical program advancing a proprietary small molecule series targeting mechanisms distinct from currently approved antiseizure medications for the treatment of drug-resistant epilepsy. Preclinical studies have shown antiseizure activities in multiple models, with potential to address co-occurring anxiety symptoms. Development candidate will be nominated in 2H 2026.
• SENS-08 Discovery program advancing proprietary small molecules for cognitive dysfunction associated with neurodegenerative disease, an area with significant unmet medical need and few pharmacologic treatment options. Originates from a natural product with a long-documented history of human use. In early preclinical development and supported by a $3.5M NIH award.
• SensAI Discovery Platform Proprietary AI-powered drug discovery platform integrating expert-curated natural product data, proprietary AI tools, and chemical analysis to identify patterns across 50+ million curated data relationships (including >700K natural products, >100K plants, >250K ethnobotanical references, >1M bioassays). Used internally by Sensorium Therapeutics to generate and advance its CNS drug pipeline; not sold as a standalone offering.

Quantifiable outcome

• Phase 1a topline results expected in second half of 2026 for SNTX-2643
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Harvard Medical SchoolcoreStrategic or Co-development PartnerScientific founders include Stephen Haggarty, PhD (Professor of Neurology, Harvard Medical School) and Jacob Hooker, PhD (Professor of Radiology, Harvard Medical School). Founded by researchers from Harvard and Massachusetts General Hospital.
• Massachusetts General HospitalcoreStrategic or Co-development PartnerJerrold Rosenbaum, MD is Co-Founder and Chair Emeritus of MGH Department of Psychiatry. Maurizio Fava, MD serves as Psychiatrist-In-Chief at MGH and Scientific Advisor to Sensorium. Founded by researchers from Harvard and Massachusetts General Hospital.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Sage Therapeutics: Clinical-stage CNS biopharmaceutical company focused on depression and other CNS disorders (zuranolone). Directly comparable to Sensorium given its CNS focus, similar clinical stage, and Sensorium's CMO Cole Brown previously held R&D and commercialization roles at Sage Therapeutics.
• Axsome Therapeutics: Commercial-stage CNS biopharmaceutical company developing therapies for depression, migraine, and narcolepsy. Comparable to Sensorium as a small-molecule CNS therapeutics developer targeting anxiety and depression with differentiated mechanisms, though at a more advanced commercial stage.
• Compass Pathways: Mental health care company developing psilocybin-based therapies for treatment-resistant depression. Directly comparable to Sensorium as a company developing psychoactive/neuroactive CNS medicines, with a similar focus on differentiated mechanisms for underserved psychiatric indications.
• MindMed: Clinical-stage neuropsychiatric company developing psychedelic-inspired medicines for anxiety, depression, and other CNS disorders. Comparable to Sensorium as a peer developing novel psychoactive CNS therapeutics with a focus on anxiety disorders.
• Delix Therapeutics: Clinical-stage neuroscience company developing neuroplastogens for depression, anxiety, and other CNS disorders. Directly comparable to Sensorium — co-founder Jacob Hooker also co-founded and advised Delix Therapeutics, and both companies focus on novel-mechanism CNS therapeutics.
• Alto Neuroscience: Clinical-stage CNS biopharmaceutical company applying a precision psychiatry approach to develop novel treatments for depression and other CNS disorders. Comparable to Sensorium as a clinical-stage biotech targeting anxiety/depression with a differentiated mechanistic approach.
• Neumora Therapeutics: Clinical-stage biopharmaceutical company developing precision medicines for brain diseases including depression. Comparable to Sensorium as a CNS-focused clinical-stage biotech targeting depression/anxiety with differentiated mechanisms.

Broad incumbents

• Karuna Therapeutics: CNS biopharmaceutical company developing xanomeline-trospium for schizophrenia and psychosis (acquired by Bristol Myers Squibb). Comparable as a clinical-stage CNS therapeutics company addressing underserved psychiatric indications, though at a more advanced stage.
• Janssen Pharmaceuticals (Johnson & Johnson): Major pharmaceutical division of Johnson & Johnson with Spravato (esketamine) for treatment-resistant depression. Comparable as a broad incumbent with an approved rapid-acting psychoactive CNS therapy, representing both a competitive benchmark and a potential strategic acquirer/partner for Sensorium.

Emerging players

• Cybin: Clinical-stage psychedelics company developing deuterated psilocybin analogs and other psychedelic-based therapies for depression and anxiety. Comparable to Sensorium as an emerging player in the psychoactive CNS therapeutics space, though focused specifically on psychedelic derivatives.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds2 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sensorium Therapeutics